|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:CHEK2-C22orf31 (FusionGDB2 ID:16418) |
Fusion Gene Summary for CHEK2-C22orf31 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CHEK2-C22orf31 | Fusion gene ID: 16418 | Hgene | Tgene | Gene symbol | CHEK2 | C22orf31 | Gene ID | 11200 | 25770 |
| Gene name | checkpoint kinase 2 | chromosome 22 open reading frame 31 | |
| Synonyms | CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|hCds1 | HS747E2A|bK747E2.1 | |
| Cytomap | 22q12.1 | 22q12.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | serine/threonine-protein kinase Chk2CHK2 checkpoint homologcds1 homologcheckpoint-like protein CHK2 | uncharacterized protein C22orf31 | |
| Modification date | 20200320 | 20200313 | |
| UniProtAcc | O96017 | O95567 | |
| Ensembl transtripts involved in fusion gene | ENST00000544772, ENST00000328354, ENST00000348295, ENST00000382565, ENST00000382578, ENST00000382580, ENST00000405598, ENST00000382566, ENST00000402731, ENST00000403642, ENST00000404276, ENST00000464581, | ENST00000216071, | |
| Fusion gene scores | * DoF score | 3 X 3 X 3=27 | 5 X 3 X 4=60 |
| # samples | 3 | 5 | |
| ** MAII score | log2(3/27*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(5/60*10)=-0.263034405833794 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: CHEK2 [Title/Abstract] AND C22orf31 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | CHEK2(29130391)-C22orf31(29456831), # samples:2 | ||
| Anticipated loss of major functional domain due to fusion event. | CHEK2-C22orf31 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. CHEK2-C22orf31 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. CHEK2-C22orf31 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. CHEK2-C22orf31 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CHEK2 | GO:0006355 | regulation of transcription, DNA-templated | 12717439 |
| Hgene | CHEK2 | GO:0006468 | protein phosphorylation | 12717439 |
| Hgene | CHEK2 | GO:0006974 | cellular response to DNA damage stimulus | 24550317 |
| Hgene | CHEK2 | GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage | 12402044 |
| Hgene | CHEK2 | GO:0042770 | signal transduction in response to DNA damage | 14744935 |
| Hgene | CHEK2 | GO:0045893 | positive regulation of transcription, DNA-templated | 17101782 |
| Hgene | CHEK2 | GO:0046777 | protein autophosphorylation | 16794575|18644861 |
| Hgene | CHEK2 | GO:0050821 | protein stabilization | 12717439 |
| Fusion gene breakpoints across CHEK2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene breakpoints across C22orf31 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
 |
| Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | LUSC | TCGA-NC-A5HD-01A | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
Top |
Fusion Gene ORF analysis for CHEK2-C22orf31 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5UTR-3CDS | ENST00000544772 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| Frame-shift | ENST00000328354 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| Frame-shift | ENST00000348295 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| Frame-shift | ENST00000382565 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| Frame-shift | ENST00000382578 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| Frame-shift | ENST00000382580 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| Frame-shift | ENST00000405598 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| In-frame | ENST00000382566 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| In-frame | ENST00000402731 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| In-frame | ENST00000403642 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| In-frame | ENST00000404276 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| intron-3CDS | ENST00000464581 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| ENST00000382566 | CHEK2 | chr22 | 29130391 | - | ENST00000216071 | C22orf31 | chr22 | 29456831 | - | 1331 | 391 | 295 | 1260 | 321 |
| ENST00000404276 | CHEK2 | chr22 | 29130391 | - | ENST00000216071 | C22orf31 | chr22 | 29456831 | - | 1259 | 319 | 223 | 1188 | 321 |
| ENST00000402731 | CHEK2 | chr22 | 29130391 | - | ENST00000216071 | C22orf31 | chr22 | 29456831 | - | 1259 | 319 | 223 | 1188 | 321 |
| ENST00000403642 | CHEK2 | chr22 | 29130391 | - | ENST00000216071 | C22orf31 | chr22 | 29456831 | - | 1259 | 319 | 223 | 1188 | 321 |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
| ENST00000382566 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - | 0.117582105 | 0.8824179 |
| ENST00000404276 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - | 0.11893738 | 0.8810626 |
| ENST00000402731 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - | 0.11893738 | 0.8810626 |
| ENST00000403642 | ENST00000216071 | CHEK2 | chr22 | 29130391 | - | C22orf31 | chr22 | 29456831 | - | 0.11893738 | 0.8810626 |
Top |
Fusion Genomic Features for CHEK2-C22orf31 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page. |
 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
Top |
Fusion Protein Features for CHEK2-C22orf31 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr22:29130391/chr22:29456831) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| CHEK2 | C22orf31 |
| FUNCTION: Serine/threonine-protein kinase which is required for checkpoint-mediated cell cycle arrest, activation of DNA repair and apoptosis in response to the presence of DNA double-strand breaks. May also negatively regulate cell cycle progression during unperturbed cell cycles. Following activation, phosphorylates numerous effectors preferentially at the consensus sequence [L-X-R-X-X-S/T]. Regulates cell cycle checkpoint arrest through phosphorylation of CDC25A, CDC25B and CDC25C, inhibiting their activity. Inhibition of CDC25 phosphatase activity leads to increased inhibitory tyrosine phosphorylation of CDK-cyclin complexes and blocks cell cycle progression. May also phosphorylate NEK6 which is involved in G2/M cell cycle arrest. Regulates DNA repair through phosphorylation of BRCA2, enhancing the association of RAD51 with chromatin which promotes DNA repair by homologous recombination. Also stimulates the transcription of genes involved in DNA repair (including BRCA2) through the phosphorylation and activation of the transcription factor FOXM1. Regulates apoptosis through the phosphorylation of p53/TP53, MDM4 and PML. Phosphorylation of p53/TP53 at 'Ser-20' by CHEK2 may alleviate inhibition by MDM2, leading to accumulation of active p53/TP53. Phosphorylation of MDM4 may also reduce degradation of p53/TP53. Also controls the transcription of pro-apoptotic genes through phosphorylation of the transcription factor E2F1. Tumor suppressor, it may also have a DNA damage-independent function in mitotic spindle assembly by phosphorylating BRCA1. Its absence may be a cause of the chromosomal instability observed in some cancer cells. Promotes the CCAR2-SIRT1 association and is required for CCAR2-mediated SIRT1 inhibition (PubMed:25361978). {ECO:0000250|UniProtKB:Q9Z265, ECO:0000269|PubMed:10097108, ECO:0000269|PubMed:10724175, ECO:0000269|PubMed:11298456, ECO:0000269|PubMed:12402044, ECO:0000269|PubMed:12607004, ECO:0000269|PubMed:12717439, ECO:0000269|PubMed:12810724, ECO:0000269|PubMed:16163388, ECO:0000269|PubMed:17101782, ECO:0000269|PubMed:17380128, ECO:0000269|PubMed:17715138, ECO:0000269|PubMed:18317453, ECO:0000269|PubMed:18644861, ECO:0000269|PubMed:18728393, ECO:0000269|PubMed:20364141, ECO:0000269|PubMed:25361978, ECO:0000269|PubMed:25619829, ECO:0000269|PubMed:9836640, ECO:0000269|PubMed:9889122}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000328354 | - | 2 | 15 | 113_175 | 106 | 544.0 | Domain | FHA |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000328354 | - | 2 | 15 | 220_486 | 106 | 544.0 | Domain | Protein kinase |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000348295 | - | 2 | 14 | 113_175 | 106 | 515.0 | Domain | FHA |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000348295 | - | 2 | 14 | 220_486 | 106 | 515.0 | Domain | Protein kinase |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382566 | - | 2 | 14 | 113_175 | 106 | 276.6666666666667 | Domain | FHA |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382566 | - | 2 | 14 | 220_486 | 106 | 276.6666666666667 | Domain | Protein kinase |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382578 | - | 2 | 13 | 113_175 | 106 | 453.0 | Domain | FHA |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382578 | - | 2 | 13 | 220_486 | 106 | 453.0 | Domain | Protein kinase |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382580 | - | 2 | 16 | 113_175 | 106 | 587.0 | Domain | FHA |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382580 | - | 2 | 16 | 220_486 | 106 | 587.0 | Domain | Protein kinase |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000402731 | - | 1 | 13 | 113_175 | 106 | 515.0 | Domain | FHA |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000402731 | - | 1 | 13 | 220_486 | 106 | 515.0 | Domain | Protein kinase |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000403642 | - | 1 | 12 | 113_175 | 106 | 453.0 | Domain | FHA |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000403642 | - | 1 | 12 | 220_486 | 106 | 453.0 | Domain | Protein kinase |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000404276 | - | 1 | 14 | 113_175 | 106 | 544.0 | Domain | FHA |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000404276 | - | 1 | 14 | 220_486 | 106 | 544.0 | Domain | Protein kinase |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000405598 | - | 3 | 16 | 113_175 | 106 | 544.0 | Domain | FHA |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000405598 | - | 3 | 16 | 220_486 | 106 | 544.0 | Domain | Protein kinase |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000544772 | - | 2 | 16 | 113_175 | 0 | 323.0 | Domain | FHA |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000544772 | - | 2 | 16 | 220_486 | 0 | 323.0 | Domain | Protein kinase |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000328354 | - | 2 | 15 | 227_234 | 106 | 544.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000328354 | - | 2 | 15 | 302_308 | 106 | 544.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000328354 | - | 2 | 15 | 351_352 | 106 | 544.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000348295 | - | 2 | 14 | 227_234 | 106 | 515.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000348295 | - | 2 | 14 | 302_308 | 106 | 515.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000348295 | - | 2 | 14 | 351_352 | 106 | 515.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382566 | - | 2 | 14 | 227_234 | 106 | 276.6666666666667 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382566 | - | 2 | 14 | 302_308 | 106 | 276.6666666666667 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382566 | - | 2 | 14 | 351_352 | 106 | 276.6666666666667 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382578 | - | 2 | 13 | 227_234 | 106 | 453.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382578 | - | 2 | 13 | 302_308 | 106 | 453.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382578 | - | 2 | 13 | 351_352 | 106 | 453.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382580 | - | 2 | 16 | 227_234 | 106 | 587.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382580 | - | 2 | 16 | 302_308 | 106 | 587.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382580 | - | 2 | 16 | 351_352 | 106 | 587.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000402731 | - | 1 | 13 | 227_234 | 106 | 515.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000402731 | - | 1 | 13 | 302_308 | 106 | 515.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000402731 | - | 1 | 13 | 351_352 | 106 | 515.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000403642 | - | 1 | 12 | 227_234 | 106 | 453.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000403642 | - | 1 | 12 | 302_308 | 106 | 453.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000403642 | - | 1 | 12 | 351_352 | 106 | 453.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000404276 | - | 1 | 14 | 227_234 | 106 | 544.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000404276 | - | 1 | 14 | 302_308 | 106 | 544.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000404276 | - | 1 | 14 | 351_352 | 106 | 544.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000405598 | - | 3 | 16 | 227_234 | 106 | 544.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000405598 | - | 3 | 16 | 302_308 | 106 | 544.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000405598 | - | 3 | 16 | 351_352 | 106 | 544.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000544772 | - | 2 | 16 | 227_234 | 0 | 323.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000544772 | - | 2 | 16 | 302_308 | 0 | 323.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000544772 | - | 2 | 16 | 351_352 | 0 | 323.0 | Nucleotide binding | Note=ATP |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000328354 | - | 2 | 15 | 368_394 | 106 | 544.0 | Region | Note=T-loop/activation segment |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000348295 | - | 2 | 14 | 368_394 | 106 | 515.0 | Region | Note=T-loop/activation segment |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382566 | - | 2 | 14 | 368_394 | 106 | 276.6666666666667 | Region | Note=T-loop/activation segment |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382578 | - | 2 | 13 | 368_394 | 106 | 453.0 | Region | Note=T-loop/activation segment |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000382580 | - | 2 | 16 | 368_394 | 106 | 587.0 | Region | Note=T-loop/activation segment |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000402731 | - | 1 | 13 | 368_394 | 106 | 515.0 | Region | Note=T-loop/activation segment |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000403642 | - | 1 | 12 | 368_394 | 106 | 453.0 | Region | Note=T-loop/activation segment |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000404276 | - | 1 | 14 | 368_394 | 106 | 544.0 | Region | Note=T-loop/activation segment |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000405598 | - | 3 | 16 | 368_394 | 106 | 544.0 | Region | Note=T-loop/activation segment |
| Hgene | CHEK2 | chr22:29130391 | chr22:29456831 | ENST00000544772 | - | 2 | 16 | 368_394 | 0 | 323.0 | Region | Note=T-loop/activation segment |
Top |
Fusion Gene Sequence for CHEK2-C22orf31 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >16418_16418_1_CHEK2-C22orf31_CHEK2_chr22_29130391_ENST00000382566_C22orf31_chr22_29456831_ENST00000216071_length(transcript)=1331nt_BP=391nt GCAGGTTTAGCGCCACTCTGCTGGCTGAGGCTGCGGAGAGTGTGCGGCTCCAGGTGGGCTCACGCGGTCGTGATGTCTCGGGAGTCGGAT GTTGAGGCTCAGCAGTCTCATGGCAGCAGTGCCTGTTCACAGCCCCATGGCAGCGTTACCCAGTCCCAAGGCTCCTCCTCACAGTCCCAG GGCATATCCAGCTCCTCTACCAGCACGATGCCAAACTCCAGCCAGTCCTCTCACTCCAGCTCTGGGACACTGAGCTCCTTAGAGACAGTG TCCACTCAGGAACTCTATTCTATTCCTGAGGACCAAGAACCTGAGGACCAAGAACCTGAGGAGCCTACCCCTGCCCCCTGGGCTCGATTA TGGGCCCTTCAGGATGGATTTGCCAATCTTGCACCCAATCAATGTGAGACGAGACCCCAGCATCCCTATCTATGGACTCCGACAGTCCAT CTTATTAAATACCAGGCTTCAGGACTGCTATGTGGACTCACCGGCTCTCACCAACATCTGGATGGCCAGAACATGTGCAAAGCAGAACAT TAATGCCCCAGCACCAGCTACCACTTCCTCTTGGGAAGTTGTAAGGAACCCATTAATTGCCAGTTCCTTCTCCCTGGTTAAGCTTGTACT CAGGCGGCAACTGAAGAATAAGTGCTGCCCACCACCATGCAAGTTTGGAGAAGGAAAACTCTCGAAGAGATTAAAGCACAAGGACGATTC AGTGATGAAAGCCACCCAGCAGGCCAGGAAAAGAAACTTCATCAGTTCCAAGAGCAAGCAGCCAGCAGGGCATAGGAGGCCTGCAGGAGG CATCAGAGAGAGTAAAGAAAGTTCAAAGGAGAAAAAACTAACAGTCCGCCAAGATCTTGAGGACAGATATGCTGAACATGTGGCTGCCAC CCAAGCGCTACCCCAGGACAGTGGGACAGCAGCCTGGAAGGGCCGAGTGTTGCTTCCTGAAACCCAAAAGAGACAGCAGTTGTCGGAGGA CACGCTAACCATCCATGGTCTCCCCACAGAGGGTTACCAGGCTCTGTACCACGCTGTGGTGGAGCCAATGCTGTGGAATCCTTCAGGGAC CCCCAAGAGGTACAGCCTGGAGCTGGGCAAGGCCATTAAACAAAAGCTCTGGGAGGCTCTTTGCAGTCAGGGTGCCATCTCTGAAGGTGC TCAGAGGGACCGGTTCCCTGGCAGGAAGCAGCCAGGTGTCCACGAGGAGCCTGTACTCAAGAAATGGCCCAAGTTAAAGAGCAAAAAATA >16418_16418_1_CHEK2-C22orf31_CHEK2_chr22_29130391_ENST00000382566_C22orf31_chr22_29456831_ENST00000216071_length(amino acids)=321AA_BP=25 MRTKNLRTKNLRSLPLPPGLDYGPFRMDLPILHPINVRRDPSIPIYGLRQSILLNTRLQDCYVDSPALTNIWMARTCAKQNINAPAPATT SSWEVVRNPLIASSFSLVKLVLRRQLKNKCCPPPCKFGEGKLSKRLKHKDDSVMKATQQARKRNFISSKSKQPAGHRRPAGGIRESKESS KEKKLTVRQDLEDRYAEHVAATQALPQDSGTAAWKGRVLLPETQKRQQLSEDTLTIHGLPTEGYQALYHAVVEPMLWNPSGTPKRYSLEL -------------------------------------------------------------- >16418_16418_2_CHEK2-C22orf31_CHEK2_chr22_29130391_ENST00000402731_C22orf31_chr22_29456831_ENST00000216071_length(transcript)=1259nt_BP=319nt ATGTCTCGGGAGTCGGATGTTGAGGCTCAGCAGTCTCATGGCAGCAGTGCCTGTTCACAGCCCCATGGCAGCGTTACCCAGTCCCAAGGC TCCTCCTCACAGTCCCAGGGCATATCCAGCTCCTCTACCAGCACGATGCCAAACTCCAGCCAGTCCTCTCACTCCAGCTCTGGGACACTG AGCTCCTTAGAGACAGTGTCCACTCAGGAACTCTATTCTATTCCTGAGGACCAAGAACCTGAGGACCAAGAACCTGAGGAGCCTACCCCT GCCCCCTGGGCTCGATTATGGGCCCTTCAGGATGGATTTGCCAATCTTGCACCCAATCAATGTGAGACGAGACCCCAGCATCCCTATCTA TGGACTCCGACAGTCCATCTTATTAAATACCAGGCTTCAGGACTGCTATGTGGACTCACCGGCTCTCACCAACATCTGGATGGCCAGAAC ATGTGCAAAGCAGAACATTAATGCCCCAGCACCAGCTACCACTTCCTCTTGGGAAGTTGTAAGGAACCCATTAATTGCCAGTTCCTTCTC CCTGGTTAAGCTTGTACTCAGGCGGCAACTGAAGAATAAGTGCTGCCCACCACCATGCAAGTTTGGAGAAGGAAAACTCTCGAAGAGATT AAAGCACAAGGACGATTCAGTGATGAAAGCCACCCAGCAGGCCAGGAAAAGAAACTTCATCAGTTCCAAGAGCAAGCAGCCAGCAGGGCA TAGGAGGCCTGCAGGAGGCATCAGAGAGAGTAAAGAAAGTTCAAAGGAGAAAAAACTAACAGTCCGCCAAGATCTTGAGGACAGATATGC TGAACATGTGGCTGCCACCCAAGCGCTACCCCAGGACAGTGGGACAGCAGCCTGGAAGGGCCGAGTGTTGCTTCCTGAAACCCAAAAGAG ACAGCAGTTGTCGGAGGACACGCTAACCATCCATGGTCTCCCCACAGAGGGTTACCAGGCTCTGTACCACGCTGTGGTGGAGCCAATGCT GTGGAATCCTTCAGGGACCCCCAAGAGGTACAGCCTGGAGCTGGGCAAGGCCATTAAACAAAAGCTCTGGGAGGCTCTTTGCAGTCAGGG TGCCATCTCTGAAGGTGCTCAGAGGGACCGGTTCCCTGGCAGGAAGCAGCCAGGTGTCCACGAGGAGCCTGTACTCAAGAAATGGCCCAA >16418_16418_2_CHEK2-C22orf31_CHEK2_chr22_29130391_ENST00000402731_C22orf31_chr22_29456831_ENST00000216071_length(amino acids)=321AA_BP=25 MRTKNLRTKNLRSLPLPPGLDYGPFRMDLPILHPINVRRDPSIPIYGLRQSILLNTRLQDCYVDSPALTNIWMARTCAKQNINAPAPATT SSWEVVRNPLIASSFSLVKLVLRRQLKNKCCPPPCKFGEGKLSKRLKHKDDSVMKATQQARKRNFISSKSKQPAGHRRPAGGIRESKESS KEKKLTVRQDLEDRYAEHVAATQALPQDSGTAAWKGRVLLPETQKRQQLSEDTLTIHGLPTEGYQALYHAVVEPMLWNPSGTPKRYSLEL -------------------------------------------------------------- >16418_16418_3_CHEK2-C22orf31_CHEK2_chr22_29130391_ENST00000403642_C22orf31_chr22_29456831_ENST00000216071_length(transcript)=1259nt_BP=319nt ATGTCTCGGGAGTCGGATGTTGAGGCTCAGCAGTCTCATGGCAGCAGTGCCTGTTCACAGCCCCATGGCAGCGTTACCCAGTCCCAAGGC TCCTCCTCACAGTCCCAGGGCATATCCAGCTCCTCTACCAGCACGATGCCAAACTCCAGCCAGTCCTCTCACTCCAGCTCTGGGACACTG AGCTCCTTAGAGACAGTGTCCACTCAGGAACTCTATTCTATTCCTGAGGACCAAGAACCTGAGGACCAAGAACCTGAGGAGCCTACCCCT GCCCCCTGGGCTCGATTATGGGCCCTTCAGGATGGATTTGCCAATCTTGCACCCAATCAATGTGAGACGAGACCCCAGCATCCCTATCTA TGGACTCCGACAGTCCATCTTATTAAATACCAGGCTTCAGGACTGCTATGTGGACTCACCGGCTCTCACCAACATCTGGATGGCCAGAAC ATGTGCAAAGCAGAACATTAATGCCCCAGCACCAGCTACCACTTCCTCTTGGGAAGTTGTAAGGAACCCATTAATTGCCAGTTCCTTCTC CCTGGTTAAGCTTGTACTCAGGCGGCAACTGAAGAATAAGTGCTGCCCACCACCATGCAAGTTTGGAGAAGGAAAACTCTCGAAGAGATT AAAGCACAAGGACGATTCAGTGATGAAAGCCACCCAGCAGGCCAGGAAAAGAAACTTCATCAGTTCCAAGAGCAAGCAGCCAGCAGGGCA TAGGAGGCCTGCAGGAGGCATCAGAGAGAGTAAAGAAAGTTCAAAGGAGAAAAAACTAACAGTCCGCCAAGATCTTGAGGACAGATATGC TGAACATGTGGCTGCCACCCAAGCGCTACCCCAGGACAGTGGGACAGCAGCCTGGAAGGGCCGAGTGTTGCTTCCTGAAACCCAAAAGAG ACAGCAGTTGTCGGAGGACACGCTAACCATCCATGGTCTCCCCACAGAGGGTTACCAGGCTCTGTACCACGCTGTGGTGGAGCCAATGCT GTGGAATCCTTCAGGGACCCCCAAGAGGTACAGCCTGGAGCTGGGCAAGGCCATTAAACAAAAGCTCTGGGAGGCTCTTTGCAGTCAGGG TGCCATCTCTGAAGGTGCTCAGAGGGACCGGTTCCCTGGCAGGAAGCAGCCAGGTGTCCACGAGGAGCCTGTACTCAAGAAATGGCCCAA >16418_16418_3_CHEK2-C22orf31_CHEK2_chr22_29130391_ENST00000403642_C22orf31_chr22_29456831_ENST00000216071_length(amino acids)=321AA_BP=25 MRTKNLRTKNLRSLPLPPGLDYGPFRMDLPILHPINVRRDPSIPIYGLRQSILLNTRLQDCYVDSPALTNIWMARTCAKQNINAPAPATT SSWEVVRNPLIASSFSLVKLVLRRQLKNKCCPPPCKFGEGKLSKRLKHKDDSVMKATQQARKRNFISSKSKQPAGHRRPAGGIRESKESS KEKKLTVRQDLEDRYAEHVAATQALPQDSGTAAWKGRVLLPETQKRQQLSEDTLTIHGLPTEGYQALYHAVVEPMLWNPSGTPKRYSLEL -------------------------------------------------------------- >16418_16418_4_CHEK2-C22orf31_CHEK2_chr22_29130391_ENST00000404276_C22orf31_chr22_29456831_ENST00000216071_length(transcript)=1259nt_BP=319nt ATGTCTCGGGAGTCGGATGTTGAGGCTCAGCAGTCTCATGGCAGCAGTGCCTGTTCACAGCCCCATGGCAGCGTTACCCAGTCCCAAGGC TCCTCCTCACAGTCCCAGGGCATATCCAGCTCCTCTACCAGCACGATGCCAAACTCCAGCCAGTCCTCTCACTCCAGCTCTGGGACACTG AGCTCCTTAGAGACAGTGTCCACTCAGGAACTCTATTCTATTCCTGAGGACCAAGAACCTGAGGACCAAGAACCTGAGGAGCCTACCCCT GCCCCCTGGGCTCGATTATGGGCCCTTCAGGATGGATTTGCCAATCTTGCACCCAATCAATGTGAGACGAGACCCCAGCATCCCTATCTA TGGACTCCGACAGTCCATCTTATTAAATACCAGGCTTCAGGACTGCTATGTGGACTCACCGGCTCTCACCAACATCTGGATGGCCAGAAC ATGTGCAAAGCAGAACATTAATGCCCCAGCACCAGCTACCACTTCCTCTTGGGAAGTTGTAAGGAACCCATTAATTGCCAGTTCCTTCTC CCTGGTTAAGCTTGTACTCAGGCGGCAACTGAAGAATAAGTGCTGCCCACCACCATGCAAGTTTGGAGAAGGAAAACTCTCGAAGAGATT AAAGCACAAGGACGATTCAGTGATGAAAGCCACCCAGCAGGCCAGGAAAAGAAACTTCATCAGTTCCAAGAGCAAGCAGCCAGCAGGGCA TAGGAGGCCTGCAGGAGGCATCAGAGAGAGTAAAGAAAGTTCAAAGGAGAAAAAACTAACAGTCCGCCAAGATCTTGAGGACAGATATGC TGAACATGTGGCTGCCACCCAAGCGCTACCCCAGGACAGTGGGACAGCAGCCTGGAAGGGCCGAGTGTTGCTTCCTGAAACCCAAAAGAG ACAGCAGTTGTCGGAGGACACGCTAACCATCCATGGTCTCCCCACAGAGGGTTACCAGGCTCTGTACCACGCTGTGGTGGAGCCAATGCT GTGGAATCCTTCAGGGACCCCCAAGAGGTACAGCCTGGAGCTGGGCAAGGCCATTAAACAAAAGCTCTGGGAGGCTCTTTGCAGTCAGGG TGCCATCTCTGAAGGTGCTCAGAGGGACCGGTTCCCTGGCAGGAAGCAGCCAGGTGTCCACGAGGAGCCTGTACTCAAGAAATGGCCCAA >16418_16418_4_CHEK2-C22orf31_CHEK2_chr22_29130391_ENST00000404276_C22orf31_chr22_29456831_ENST00000216071_length(amino acids)=321AA_BP=25 MRTKNLRTKNLRSLPLPPGLDYGPFRMDLPILHPINVRRDPSIPIYGLRQSILLNTRLQDCYVDSPALTNIWMARTCAKQNINAPAPATT SSWEVVRNPLIASSFSLVKLVLRRQLKNKCCPPPCKFGEGKLSKRLKHKDDSVMKATQQARKRNFISSKSKQPAGHRRPAGGIRESKESS KEKKLTVRQDLEDRYAEHVAATQALPQDSGTAAWKGRVLLPETQKRQQLSEDTLTIHGLPTEGYQALYHAVVEPMLWNPSGTPKRYSLEL -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for CHEK2-C22orf31 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CHEK2-C22orf31 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for CHEK2-C22orf31 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies